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Objective: In this study, we compare the clinical and histological outcome between periosteum and
Chondrogide during autologous chondrocyte implantation (ACI).
Method: This study consisted of 88 patients having received ACI in the knee; 33 treated with
Chondrogide (ACI-C) and 55 with periosteum (ACI-P). Post-operative biopsies were taken at a mean of
16.6  8 months (range 7e37 months) and 19  18.4 months (range 4e114) for ACI-C and ACI-P
respectively. Histological assessment was performed using the ICRS II and OsScore scoring systems.
The immunolocalisation of elastin and collagen types I and II was analysed using speciﬁc antibodies.
Lysholm scores, a measure of knee function, were obtained pre- and post-operatively at the time of
biopsy and annually thereafter.
Results: Compared with ACI-P, the repair tissue formed from patients treated with ACI-C demonstrated a
signiﬁcantly higher score for cellular morphology (ICRS II score), signiﬁcantly better surface morphology
from medial femoral condyle treated defects (ICRS II score) and a signiﬁcantly higher proportion of
hyaline cartilage formation (OsScore). Elastin ﬁbres were present in both ACI-C and ACI-P samples,
although their presence was very variable in quantity, distribution, orientation, thickness and length.
Patients treated with ACI-C demonstrated signiﬁcantly more collagen type II immunolocalisation
compared with ACI-P. Both groups exhibited a signiﬁcant increase in Lysholm score post-ACI.
Conclusions: This study demonstrates a signiﬁcantly better quality of repair tissue formed with ACI-C
compared with ACI-P. Hence Chondrogide is perhaps a better alternative to periosteum during ACI.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Hyaline cartilage is a highly organised tissue composed pri-
marily of proteoglycans and type II collagenwith a small amount of
elastin1, which lacks the capability for spontaneous self-
regeneration. Symptomatic full-thickness chondral defects in
articular joints such as the knee have been treated for many years
with autologous chondrocyte implantation (ACI), a two-stage pro-
cess whereby the patient’s chondrocytes are culture-expanded
in vitro and then implanted into the defect beneath a membrane.
Traditionally, the membrane was autologous periosteum2, har-
vested from the medial proximal tibia. Periosteum has an outer
“ﬁbrous layer” consisting of ﬁbroblasts and an inner “cambiumH.S. McCarthy, Robert Jones
and ISTM, Keele University,
660.
McCarthy).
s Research Society International. Player” consisting of osteogenic progenitor cells3. It therefore has
osteogenic capacity, but in a chondrotrophic environment it can also
be used to promote cartilage formation4,5. Whilst ACI is generally
considered to provide clinical relief in most patients6,7, continued
follow-up of patients treated with a periosteal patch during ACI has
noted an increased rate of hypertrophy of the graft8,9, thus often
requiring shaving of the repair tissue overgrowth.
More recently, in an attempt to limit complications observed
with periosteal based ACI and removing the need for any incision
over the tibia, Chondrogide, a commercially available membrane
(Geistlich Pharma AG, Switzerland) consisting of porcine collagen
types I and III, has been used10. This is described by the manufac-
turers as a bilayer membrane, naturally resorbed within 24
weeks11, with a compact smooth surface preventing cells from
diffusing through the membrane and a porous layer of collagen
ﬁbres which promotes cell invasion and attachment.
A prospective randomised clinical trial by Gooding et al.,8
comparing the use of periosteum and Chondrogide for the
repair of full-thickness chondral defects in the knee concluded noublished by Elsevier Ltd. All rights reserved.
Table I
Patient, defect and biopsy details for both Chondrogide (ACI-C) and periosteum
(ACI-P) treated patients
ACI-C ACI-P
Number of patients 33 55
Age at ACI (years) 38.7  8.1 34.2  10.1*
Size of treated defect (cm2) 6.7  5.6
(range 1.1e33.75)
4.5  3*
(range 0.96e13.5)
Number of defects treated 48 62
Number of cells implanted 5.9  1.9  106
(range 3e10  106)
5.7  2.4  106
(range 1.1e12  106)
Number of patients:
single defects
22 47
Number of patients:
multiple defects
11 8
Medial femoral condyle 19 39
Lateral femoral condyle 11 12
Trochlea 8 5
Patella 4 3
Tibial plateau 5 3
Number of biopsies 45 62
Time of biopsy
(months post-ACI)
16.6  8
(range 7e37)
19  18.4
(range 4e114)
Latest follow-up
(months post-ACI)
56.5  20.1
(range 15e98)
85.2  32.6*
(range 13e157)
* Signiﬁcant differences between patch types.
Table II
Parameters assessed in the ICRS II and OsScore histology scoring systems. For the
ICRS II scoring system, each of the 14 parameters is marked out of 10 on a VAS22. For
the OsScore system, there is a total score of 10 with different parameters contrib-
uting a different weighting to the overall score17
Scoring parameter ICRS II OsScore
Tissue morphology C C
Matrix metachromasia C C
Cell morphology C
Cell clusters C C
Surface architecture C C
Basal integration C C
Calciﬁcation front/tidemark C
Subchondral bone abnormalities C
Inﬂammation C
Calciﬁcation C C
Vascularisation C C
Surface/superﬁcial assessment C
Mid/deep zone assessment C
Overall assessment C
H.S. McCarthy, S. Roberts / Osteoarthritis and Cartilage 21 (2013) 2048e2057 2049signiﬁcant difference between the two patches, based on clinical
outcome and arthroscopic assessment at 2 years. However, the use
of a collagen membrane was advocated as it is attributed with
reducing graft failure, complications and re-operation rates asso-
ciated with the use of periosteum10,12.
Whilst the patient’s clinical outcome following treatment such
as ACI is paramount, follow-up can often be lengthy and time
consuming. Therefore, the ability to use histological parameters to
assess the quality of the repair tissue at an earlier time point may
prove beneﬁcial for predicting outcome. Histology or repair tissue
biopsies has been performed in several other studies, but usually
limited to overall matrix morphology8,13,14,15 with few scoring in-
dividual parameters16,17. While studies have reported on hyper-
trophy of the graft, they fail to comment on the surface architecture.
The purpose of this study therefore was to compare the histo-
logical outcome of repair tissue when using the two different patch
types, periosteum and Chondrogide and determine if this
impacted upon clinical outcome. In addition, the presence of elastin
ﬁbres in the repair tissue was investigated to see if the elastic
network was replenished. Immunolocalisation of collagen types I
and II was also investigated.
Methods
Patients and ACI procedure
This ethically approved retrospective study (09/H1203/90)
consisted of 88 fully informed and consented patients who un-
derwent ACI treatment of cartilage defects in the knee. ACI was
performed as described by Brittberg et al.2, using a two-stage
procedure, where the ﬁrst stage required an arthroscopic removal
of a small piece of macroscopically healthy cartilage, usually from
either the intercondylar notch or trochlea. Chondrocytes were
isolated from the harvested cartilage in the GMP-approved John
Charnley Laboratory and cultured in autologous serum18. After an
average of 21 days in culture, the autologous chondrocytes were
implanted beneath a periosteal or collagen (Chondrogide) mem-
brane covering the defect.
Of these 88 patients (66 men and 22 women), 33 patients
received Chondrogide (ACI-C) and 55 patients received perios-
teum (ACI-P). In total there were 110 defects treated, 48 treated
with ACI-C and 62 treated with ACI-P with varying locations (see
details in Table I). To maximise the sample number, all sequential
patients with a biopsy of repair tissue were included, even though
this resulted in different numbers of samples for ACI-C and ACI-P.
Post-operative tissue biopsies and clinical outcome
A juvenile bone marrow biopsy needle was used during
arthroscopy to obtain a core biopsy of the repair tissue as close as
possible to the centre of the treated defect, with the aim of
acquiring both the cartilage repair tissue and the underlying sub-
chondral bone. A total of 107 repair tissue core biopsies (45 ACI-C,
62 ACI-P) of <2 mm diameter, were taken at a mean of 16.6  8
months (range 7e37 months) and 19  18.4 months (range 4e114
months) post-operatively for ACI-C and ACI-P respectively. Biopsies
were snap frozen in liquid nitrogen-cooled hexane, embedded in
OCT compound (Tissue-Tek, Zoeterwoude, The Netherlands) then
cryosectioned to produce 7 mm thick sections which were collected
onto poly-L-lysine coated slides. The remaining sample was stored
in liquid nitrogen.
Lysholm scores, a measure of knee function19, were obtained
pre- and post-operatively at the time of biopsy and annually
thereafter. The score ranges from 0 (poor outcome) to 100 (best
outcome).Histology
Frozen sections were defrosted at room temperature and
stained with either haematoxylin and eosin (H&E) for histological
assessment of the general morphology of the repair tissue, or
safranin O/fast green (Saf-O/FG) and/or toluidine blue (TB), to
indicate glycosaminoglycan content as per standard protocols20.
Sections were then analysed under polarised light microscopy to
examine collagen ﬁbre orientation and distinguish between hyaline
cartilage and ﬁbrocartilage21. The histological quality of the repair
tissue was assessed and scored using (1) the ICRS II visual analogue
scale22 (VAS, each of 14 parameters scored 0e10) and (2) the
OsScore17 (total score 0e10), assessing the parameters listed in
Table II. A higher score in each scoring system represents tissue
resembling healthy articular cartilage.Immunohistochemistry
Immunolocalisation of elastin was performed on eight biopsies
(ﬁve ACI-C and three ACI-P) and for collagen types I and II on 74
biopsies (28 ACI-C and 46 ACI-P). Cryosections were incubated with
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Fig. 1. Lysholm scores taken at pre-op, at the time of the biopsy and the latest follow-up for both ACI-C and ACI-P treated patients.
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clonal anti-alpha human-elastin antibody (1:50, Biogenesis, Ox-
ford) was applied to the sections for 90 min followed by the
secondary goat anti-rabbit biotinylated antibody for
60 min (Vectastain Elite ABC kit, Vector Laboratories, Peter-
borough)1. Antibodies against collagen type I (1:500, clone I-8H5,
MP Biomedicals, Cambridge) or type II (1:10, clone CIIC1, Devel-
opmental Studies Hybridoma Bank, Iowa) were incubated for
60 min prior to the secondary goat anti-mouse biotinylated anti-
body for 60 min (Vectastain Elite ABC kit, Vector Laboratories,
Peterborough)23. Blocking steps to minimise non-speciﬁc binding
and endogenous peroxidase activity were incorporated as appro-
priate with normal goat and normal human serum in 3% bovine
serum albumin and 0.3% hydrogen peroxide in PBS or methanol.
All incubations were performed at room temperature and sec-
tions washed with PBS three times between steps. Labelling was
enhanced with streptavidin-peroxidase (Vectastain Elite ABC kit,
Vector Laboratories, Peterborough) and visualised with dia-
minobenzadine (DAB). Adjacent sections were stained with an
isotype-matched murine IgG1 (Dako, Cambridge) for collagen
staining and rabbit IgG1 (Dako, Cambridge) for elastin staining in
place of the primary antibody as a normal control. Cryosections of
Chondrogide and periosteum were also prepared and stained for
elastin for comparison to the repair tissue.
To analyse the distribution of collagens types I and II, positive
extracellular matrix staining was recorded as a percentage of the
total area of the cartilage23.Statistical analysis
Statistical differences for the comparison of various parameters
between the two patch types were tested for via a ManneWhitney
U test and correlations were tested for via a Spearman’s Rank cor-
relation. Statistical differences between grouped frequency data of
the OsScore parameters were tested for using a Chi-squared test of
independence. All statistical analyses were performed using the
software programme Analyse-it Software Ltd, Leeds, UK. Statisti-
cal signiﬁcance was considered when P < 0.05.Results
Patient characteristics and clinical outcome
Patients having received ACI-C were signiﬁcantly older (mean
age 38.7  8.1 years) than those having received ACI-P (mean age
34.2  10.1 years) at the time of treatment (P ¼ 0.0395). The mean
size of defect treated with ACI-C was also signiﬁcantly larger than
that treated with ACI-P (P ¼ 0.0092). There was no signiﬁcant dif-
ference in the number of cells implanted between each of the two
patch types. The mean time at which post-operative biopsies were
taken was shorter for ACI-C than for ACI-P, although not signiﬁ-
cantly different. The total follow-up time was signiﬁcantly longer
for ACI-P than ACI-C patients (P ¼ 0.001). Patient baseline de-
mographics and medical data are represented in Table I.
ACI-C treated patients had a signiﬁcantly lower Lysholm score
both pre-operatively (P ¼ 0.0434) and at the time of biopsy than
ACI-P patients (P ¼ 0.0015), but no signiﬁcant difference between
the scores at the latest follow-up (Fig. 1). Within each patch type
group, there was a signiﬁcant improvement in Lysholm score from
pre-operatively to that taken at the time of biopsy (P ¼ 0.0072 and
P ¼ 0.0001 for ACI-C and ACI-P respectively), but the level of
improvement at the time of biopsy and at latest follow-up was not
signiﬁcantly different between the two groups.Histology of the repair tissue
Of the 107 post-operative biopsies analysed, there was no sig-
niﬁcant difference between the overall histology scores (either the
ICRS II or OsScore) of the repair tissue between the two groups.
Additionally, there were few signiﬁcant differences between the
individual parameters of either scoring mechanism for the two
patch types. Whilst the ICRS II scoring mechanism is performed on
a VAS, the OsScore is a nominal scoring mechanism, thus allowing
the frequencies of each individual scoring parameter between the
two patch types to be analysed.
Whilst the morphology of the matrix produced in the repair
biopsies was found to not signiﬁcantly differ between ACI-C and
H.S. McCarthy, S. Roberts / Osteoarthritis and Cartilage 21 (2013) 2048e2057 2051ACI-P by ICRS II, the OsScore demonstrated a larger proportion of
ACI-C biopsies to be of either hyaline or mixed hyaline and ﬁbro-
cartilage morphology compared to ACI-P [Fig. 2(A)]. Thus, the
presence of any hyaline cartilage (either alone or a mixture of hy-
aline and ﬁbrocartilage) was observed in signiﬁcantly more bi-
opsies from patients treated with ACI-C than those treated with
ACI-P (P ¼ 0.0103). Patients treated with ACI-P demonstrated a
signiﬁcantly larger proportion of solely ﬁbrocartilage repair tissue
than those treated with ACI-C (P ¼ 0.0011). However, ﬁbrous tissue
(the worst quality of repair tissue) was observed in 9% of ACI-C
biopsies and only 2% of ACI-P biopsies. Neither of the scoring
methods used detected any signiﬁcant differences in the proteo-
glycan content between the two patch types with over 80% of bi-
opsies from both ACI-C and ACI-P groups exhibiting normal or near
normal matrix metachromasia.
Repair tissue biopsies from patients treated with ACI-C had
signiﬁcantly higher score for cellular morphology than those
treated with ACI-P (P ¼ 0.0057, [Fig. 2(B)]), with no signiﬁcant
difference in the presence of chondrocyte clusters between the two
patch types. Small clusters were relatively common whereas large
clusters were rare.
Collectively, the surface architecture of the repair tissue formed
post-ACI did not differ signiﬁcantly between the two patch types.
However, when analysing biopsies from individual locations, pa-
tients with a single defect on the MFC, had signiﬁcantly better
surface architecture when treated with ACI-C than with ACI-P
(P ¼ 0.0223 (OsScore), [Fig. 2(C)]; P ¼ 0.0451, (ICRS II) [Fig. 2(D)]).0
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Fig. 2. Histological and morphological differences of the repair tissue biopsies from ACI-C a
hyaline cartilage formation in the repair tissue than ACI-P treated patients (A), with signiﬁ
defects (C and D) and signiﬁcantly better basal integration on LFC defects (E). Collectively, ov
average basal integration (F). Graphs are presented as the percentage frequency of occurrenc
and F).No other location yielded any signiﬁcant difference in surface ar-
chitecture between the two patch types.
No signiﬁcant differences were found between ACI-C and ACI-P
repair tissue with regards to tidemark formation or subchondral
bone abnormalities. Collectively, over 90% of all biopsies, regardless
of defect location, from both ACI-C and ACI-P treated patients
exhibited either good or average basal integration of the repair
cartilage with the underlying subchondral bone (OsScore,
[Fig. 2(E)]). However, with respect to the different defect locations,
patients having received ACI for a single defect on the LFC had
signiﬁcantly better basal integration of the repair tissue with the
underlying subchondral bone when treated with ACI-P than ACI-C
when scored with the ICRS II scoring system (P ¼ 0.024,
[Fig. 2(F)]). No other location demonstrated a signiﬁcant difference
in basal integration. The majority of biopsies in both groups were
free of ectopic calciﬁcation and vascularisation and the occurrence
of extensive calciﬁcation or vascularisation were rare. No evidence
of inﬂammation was observed in any of the 107 biopsies.
For ACI-C treated patients, only the ICRS II parameter for tide-
mark formation correlated signiﬁcantly with the Lysholm score
reported at the time of the biopsy (P ¼ 0.0179, R2 ¼ 0.1914,
[Fig. 3(A)]). For ACI-P treated patients, only the ICRS II overall
parameter was found to correlate with the Lysholm score at the
time of biopsy (P ¼ 0.05, R2 ¼ 0.0311, [Fig. 3(B)]).
Nine patients (three ACI-C and six ACI-P) had multiple biopsies
taken at two different time points with an average of 34.8  31.1
months (range 12e106 months) between each biopsy. While some0
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H.S. McCarthy, S. Roberts / Osteoarthritis and Cartilage 21 (2013) 2048e20572052patient’s histology improved with time, others did not and some
remained the same, likewise with the Lysholm scores obtained at
the time of each biopsy. There was no correlation between either
the OsScore or ICRS II overall parameter, with the Lysholm score.
Immunohistochemistry for elastin, collagen type I and collagen
type II
Elastin ﬁbres were visible in approximately 31% of H&E-stained
sections (nine ACI-C and seven ACI-P). These were conﬁrmed as
elastin by performing immunohistochemistry on ﬁve ACI-C and
three ACI-P. The size of the elastin ﬁbres varied from wide ﬁbres,
visible on H&E-stained sections ([Fig. 4(A) and (B)]) and stained
light blue with Saf-O/FG [Fig. 4(C)], to apparently long and very ﬁne
ﬁbres, only visible with immunostaining [Fig. 4(D)]. Under polar-
ised light, some elastin ﬁbres could be seen to run parallel with
collagen ﬁbres [Fig. 4(E)]. The presence of elastin ﬁbres in the repair
tissue biopsies was very variable in quantity, distribution, orien-
tation, thickness and length. Elastin could be observed throughout
the depth of the cartilage or conﬁned to one, but no speciﬁc area in
both tissues with hyaline cartilage morphology and ﬁbrocartilage
[Fig. 4(F) and (G)]. Elastin ﬁbres were abundant throughout the
section of both Chondrogide [Fig. 4(H)] and periosteum [Fig. 4(I)].
Immunolocalisation of collagen types I and II was variable
throughout the repair biopsies (see Fig. 5). The area of positive
staining for both patch types ranged from 0 to 100% of the extra-
cellular matrix. There was a signiﬁcantly greater amount of positive
extracellular matrix staining for collagen type I compared to
collagen type II for both ACI-C (P ¼ 0.0252, Table III) and ACI-P
(P < 0.0001). Whilst there was no signiﬁcant difference in posi-
tive extracellular matrix staining for collagen type I between the
two patch types, there was signiﬁcantly more staining for collagen
type II in ACI-C biopsies than ACI-P biopsies (P ¼ 0.0008). The
majority of biopsies, even those with hyaline cartilage morphology,
stained positive for both collagen type I and II, but to varying de-
grees. Ninety-three per cent of ACI-C biopsies and 85% of ACI-P
biopsies stained for collagen type I exhibited over 90% positive0
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Fig. 3. Positive, but weak correlations were observed between the ICRS II scoring
parameters for tidemark formation for ACI-C patients (A) and overall score for ACI-P
patients (B) vs the Lysholm score obtained at the time of the biopsy.extracellular matrix staining throughout the depth of the tissue.
However, for those biopsies which exhibited less than 90% positive
extracellular matrix staining in either patch type group, staining
was restricted to the superﬁcial zone. Two biopsies, one from each
patch type, failed to show any positive immunolocalisation for
collagen type I.
Immunolocalisation of collagen type II however was more var-
ied. Sixty-one per cent of ACI-C biopsies and 25% of ACI-P biopsies
stained for collagen type II exhibited 100% positive extracellular
matrix staining throughout the depth of the tissue. For the
remaining biopsies with less than 100% positive extracellular
staining, no staining was observed in the superﬁcial zone except for
two biopsies (ACI-P only). Only three biopsies, all from the ACI-P
group, failed to show any positive immunolocalisation for
collagen type II.Discussion
Periosteum was the traditional membrane used when the
technique of ACI was ﬁrst developed2, but in more recent times, a
commercially available collagen membrane (Chondrogide) is
often used in its place. The extent to which the patch used in ACI
procedures contributes to the repair tissue is unknown and few
studies have compared these two patches in terms of the quality of
the repair tissue formed. It is known that periosteum contains
mesenchymal stem cells24 and has both osteogenic25,26 and chon-
drogenic potential27. Howmuch these or other cells present within
the periosteummight contribute to the repair tissue, either directly
or indirectly, has been debated5,28 but recent in vivo studies have
demonstrated the ability of periosteal cells to inﬁltrate scaffolds
and produce a cartilaginous matrix29.
Cost-effectiveness analysis in the USA comparing the use of a
periosteal patch with a commercially available collagen membrane
revealed that whilst both treatments were cost-effective in their
own right, ACI-C was marginally better value due to fewer patch-
related complications such as graft hypertrophy30. Although no
similar analyses have been performed in the UK, it is highly likely
the same results apply. While autologous periosteum is biologically
compatible with the patient, is cost-free and may be a source of
cells and growth factors, harvesting periosteum does require the
patient to endure a further incision, thus prolonging both theatre
time and potentially, patient recovery time as well as increasing the
risk of infection. Periosteum can also vary greatly between patients,
partly due to its autologous nature and partly due to the surgeon-
to-surgeon variability during the harvesting procedure.
Chondrogide on the other hand eliminates the patch type vari-
ability between patients, removes the need for an extra incision and
saves theatre time, but obviously incurs a cost for purchasing.
Chondrogide is reported to be easier to handle in surgery than
periosteum and is less likely to tear during stitching and handling
(personal communication with Prof JB Richardson).
Clinical and macroscopic results with Chondrogide suggest
that less hypertrophy occurs than seen when using a periosteal
patch10,12,31,32. In vitro studies have proposed that dysregulated
proteinase expression within the repair tissue may result in
degradation, hypertrophy or rejection of a periosteal graft33.
Although further procedures for graft hypertrophy or rejection
were not analysed in the present study, we have demonstrated for
the ﬁrst time, signiﬁcantly better surface architecture of the repair
tissue (for defects on the MFC) when using Chondrogide
compared to periosteum by two different histological scoring
methods (although the sample sizes of the two groups were not
identical). This is despite ACI-C treated defects being both larger on
average and biopsied earlier than ACI-P treated defects. It is
Fig. 4. Thick elastin ﬁbres could be observed on H&E-stained (A, B) and Saf-O/FG stained sections where they stained light blue (C). The presence of elastin ﬁbres was also
determined by immunohistochemistry (DeI). Fibres could sometimes be seen to run in close proximity to each other in “bundles” (D) and when viewed under polarised light (E,
which is a polarised image of D), they appeared to run parallel with collagen ﬁbres. In the repair tissue biopsies, elastin ﬁbres sometimes appeared short and very ﬁne (F) and could
be observed in both hyaline cartilage “h” and ﬁbrocartilage “f” (G, polarised image of F). Images A-C and F-G are of repair tissue from patients treated with ACI-C, whilst D and E are
from patients treated with ACI-P. The presence of elastin ﬁbres was also noted in both types of patch materials per se, as seen in similarly prepared immunostained sections of
Chondrogide (H) and periosteum (I). Scale bars represent 500 mm (A) and 50 mm (BeI). Boxed section in A denotes area of higher powered image in B. Arrows point to elastin ﬁbres.
H.S. McCarthy, S. Roberts / Osteoarthritis and Cartilage 21 (2013) 2048e2057 2053believed that maturation of the tissue improves with time and this
may impact on joint function23.
The use of periosteum in treating cartilage defects by ACI has
previously been reported to stimulate the remodelling process in
the underlying subchondral bone in a sheep model34. Russlieset al.34, demonstrated a signiﬁcant increase in the bone density of
the subchondral bone in those defects treated with periosteum
compared to those treated using a collagen membrane, with no
signiﬁcant difference in the histology of the repair tissue formed
between the two patch types. Although the biopsies analysed in
Fig. 5. Representative images of full depth core biopsies immunostained for collagen type I and type II. Scale bars represent 500 mm.
H.S. McCarthy, S. Roberts / Osteoarthritis and Cartilage 21 (2013) 2048e20572054this present study were not assessed solely for the density of the
subchondral bone, one of the ICRS II scoring parameters assesses
subchondral bone abnormalities (including bone marrow ﬁbrosis,
see Table II). When scoring this parameter, any thickening of the
subchondral bone in these biopsies was taken into account. There
was not, however, any signiﬁcant difference between the two patch
types and over 90% of all biopsies analysed had good or average
integration between the repair tissue and the underlying sub-
chondral bone, regardless of defect location.The periosteum has also been associated with ossiﬁcation of
the repair tissue due to its osteogenic capacity35 which is not
surprising given it contains both osteogenic progenitor cells and
osteoblasts36. The periosteum is also highly vascularised and
contains an abundance of endothelial pericytes which also have
the capacity to differentiate into osteoblasts37. Periosteal-derived
cells have been demonstrated to secrete several isoforms of
vascular endothelial growth factor38 (VEGF). VEGF has been sug-
gested to act as an autocrine growth factor for the osteoblastic
Table III
Mean percentage area of positive extracellular matrix staining for collagen types I
and II in both ACI-C and ACI-P biopsies
ACI-C ACI-P
Collagen type I 94.2  22.0 (range 0e100) 88.0  29.3 (range 0e100)
Collagen type II 91.1  14.9* (range 50e100) 67.4  32.2*,y (range 0e100)
* Signiﬁcantly more staining for collagen type II than collagen type I.
y Signiﬁcantly less staining for collagen type II in ACI-P than ACI-C.
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calciﬁcation and vascularisation was observed, although infre-
quently, in repair tissue biopsies from both ACI-C and ACI-P
treated patients. This is in contrast to a small study by Briggs
et al.13, who failed to observe any cases of ectopic calciﬁcation
following ACI-C. While the use of periosteum could have
contributed to the formation of such features during the repair
process following ACI-P, it does not explain the presence of either
ectopic calciﬁcation or vascularisation following ACI-C. Laboratory
studies however have demonstrated that osteoblasts from scle-
rotic OA subchondral bone can induce OA chondrocyte hypertro-
phy and subsequent matrix mineralisation via the downregulation
of SOX9, COL2, PTHrP and PTH-R and the upregulation of OSF-139.
In spite of this, due to the method of ACI stage 1 where a
macroscopically healthy piece of cartilage is harvested from the
knee for chondrocyte extraction, it is anticipated that the culture-
expanded implanted chondrocytes are not of an osteoarthritic
phenotype and so may be more resistant to the inﬂuences of the
underlying subchondral bone, even if sclerotic.
The purpose of elastin in articular cartilage remains an area of
interest and although its actual function is unknown, it is thought
to have both a mechanical and biological role, such as acting as a
repository for growth factors like TGFb40. Previously, elastin ﬁbres
have been observed in both the superﬁcial zone parallel to the
articular surface and in the pericellular matrix of cells within the
superﬁcial zone in human, bovine, and equine articular carti-
lage1,40,41. It has long been established that collagen ﬁbres cross-
link with elastin ﬁbres42 and so the light blue elastin ﬁbres
observed in Saf-O/FG sections is perhaps to be expected. The vari-
ability in the thickness and alignment of elastin ﬁbres observed
within the repair tissue biopsies could be representative of the level
of maturity of the repair tissue. Consistent with results presented
here, elastin ﬁbres within the periosteum have previously been
described43. As far as we are aware, this is the ﬁrst published study
to reveal the presence of elastin in Chondrogide. It is possible
therefore, that the elastin observed within the repair tissue,
particularly those samples where the elastin was conﬁned to one
particular region, could be remnants of the patch used during ACI.
Elastin is very resistant to degradation and turnover is typically
very slow in other related connective tissues44. Synthesis of new
elastin, for example in the intervertebral disc, is exceptionally
slow44, thus further supporting the hypothesis that the elastin
observed in these repair tissue biopsies has been derived from the
original patch. Whilst Chondrogide has been reported to be
resorbed during repair11, we do not know what happens to the
periosteal patch. It is possible that periosteum is remodelled to
become part of the regenerated cartilage. If this is the case, then our
proposal of the elastin in the repair tissue (especially in themid and
deep zones) having been derived from the patch, is plausible. If
however, the periosteum remains on the surface of the repair tis-
sue, then we would expect to see elastin ﬁbres in the superﬁcial
layer only (as observed in normal human articular cartilage1);
hence we suggest that the elastin we observed could be attributed
to being produced as part of the repair process. If indeed the
observed elastin is found to be derived from the patch, its presencein biopsies as much as 15 months post treatment, implies that,
particularly in ACI-C patients, Chondrogide is not completely
resorbed within the 24 weeks as previously reported11.
Collagen type I is present in large amounts in ﬁbrocartilage and
is generally either absent from healthy articular hyaline cartilage or
present in very small amounts, whereas native hyaline cartilage
contains in excess of 90% collagen type II45. Despite this, its pres-
ence alone is not recommended as a marker for hyaline cartilage23
as it can also be seen in ﬁbrocartilage, such as the intervertebral
disc46. Collagen type I and type II have previously been shown in
repair tissue biopsies following ACI with both ﬁbrocartilaginous
and hyaline cartilage morphologies15, consistent with the results
presented here. In addition, we show a signiﬁcantly greater amount
of collagen II immunolocalisation in biopsies from the ACI-C group
compared with ACI-P, suggesting that perhaps Chondrogide is
superior to periosteum for producing a repair tissue with native-
like properties. However, it has been hypothesised that the repair
tissue formed following cell implantation resembles young,
immature cartilage with chondrogenic potential23 and may take
some considerable time to mature. Therefore, as mentioned pre-
viously, obtaining further biopsies at a later stage in recovery could
be beneﬁcial for investigating the maturity of the repair tissue over
time and its impact on clinical function.Conclusion
In this study we have analysed and compared the repair tissue
formed after ACI treatment for defects in the knee when using
either a Chondrogide or periosteal patch. Ideally, the number of
patients and site of defect per patch type group would be identical;
whilst this is possible in an animal study, the current study was
performed in human patients. We believe this to be more relevant
to the clinic, but it has the disadvantage of being less able to control
for the presentation of patients such as the site of the lesion or the
change in clinical practice from using a periosteal ﬂap to the more
common use of Chondrogide. Whilst the uneven sample numbers
could have affected the statistical analyses, the histological quality
of repair tissue formedwith ACI-C differed little from that seenwith
ACI-P. This is despite ACI-C patients being signiﬁcantly older at
treatment, having signiﬁcantly larger defects treated and having
signiﬁcantly lower pre-operative Lysholm scores than ACI-P pa-
tients. Lysholm scores obtained at the time of biopsy were main-
tained in both groups up to 13 years later and so can be predictive of
long-term ACI success, regardless of the patch type used.
These results have demonstrated for the ﬁrst time, signiﬁcantly
better surface architecture and cellular morphology within the
repair tissue when treated with ACI-C compared with ACI-P.
Additionally, a signiﬁcantly greater proportion of biopsies were
found to be of hyaline or hyaline mix morphology with a signiﬁ-
cantly greater amount of positive extracellular matrix staining for
collagen type II with ACI-C compared to ACI-P. Chondrogide
therefore provides a suitable and perhaps more appropriate alter-
native to periosteum for use as a patch in the procedure of ACI.Author contributions
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